Loading…
Denali Therapeutics Inc. is projected to rise to $22.75 by 2027, a +13% move from its current price of $20.21. DNLI is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $19.65 | $20.21 | $20.79 | 0.00% |
| May 30 | $19.42 | $20.21 | $21.03 | +0.01% |
| May 31 | $19.25 | $20.21 | $21.22 | +0.01% |
| Jun 1 | $19.11 | $20.21 | $21.38 | +0.02% |
| Jun 2 | $18.98 | $20.21 | $21.53 | +0.02% |
| Jun 3 | $18.87 | $20.22 | $21.66 | +0.03% |
| Jun 4 | $18.77 | $20.22 | $21.78 | +0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $18.77 | $20.22 | $21.78 | +0.03% |
| Week 2 | $18.20 | $20.22 | $22.47 | +0.07% |
| Week 3 | $17.79 | $20.23 | $23.01 | +0.10% |
| Week 4 | $17.44 | $20.24 | $23.48 | +0.14% |
| Week 5 | $17.14 | $20.24 | $23.91 | +0.17% |
| Week 6 | $16.88 | $20.25 | $24.30 | +0.21% |
| Week 7 | $16.64 | $20.26 | $24.66 | +0.24% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Denali Therapeutics Inc. is a biopharmaceutical company that discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. Its work spans multiple programs, including Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor for Parkinson’s disease; TAK-594/DNL593 for frontotemporal dementia-granulin; DNL126 for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
The company’s broader portfolio also features TV programs like DNL952 for Pompe disease, DNL111 for Parkinson’s and Gaucher diseases, DNL622 for Hurler syndrome, and DNL628, DNL422, and DNL921 in other programs. The company was formerly SPR Pharma Inc. and changed its name to Denali Therapeutics Inc.
in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Denali Therapeutics Inc. (DNLI) is listed with a current price of $20.21 and operates within the Healthcare sector. Its market capitalization is $3.21B and it holds the rank of 1661.
The stock’s near-term outlook is buoyant, with a forecast path that begins at the current price level and projects meaningful appreciation over the coming years. The 2026 average price is $20.21, rising through the forecast horizon to substantial gains by 2050.
A major floor 18.7% below — a decisive break under it would weaken the trend.
The nearest floor, 10.4% below — buyers have tended to step in here.
The nearest ceiling, 7.3% above — a clean break opens room to run.
A major ceiling 16.6% above — clearing it would confirm fresh momentum.
Key DNLI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DNLI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $19.27 | Buy | $19.41 | Buy |
| MA 10 | $19.07 | Buy | $19.25 | Buy |
| MA 20 | $19.14 | Buy | $19.30 | Buy |
| MA 50 | $19.66 | Buy | $19.53 | Buy |
| MA 100 | $19.77 | Buy | $19.28 | Buy |
| MA 200 | $17.89 | Buy | $18.62 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.05 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 128.31 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.09 | Buy |
| ROC (12) | 3.01 | Buy |
| Bollinger %B (20,2) | 0.93 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.17 | Sell |
| Awesome (5,34) | -0.26 | Sell |
| Ultimate (7,14,28) | 60.84 | Neutral |
| Momentum (10) | 0.75 | Buy |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 19.55 | Buy |
| ADX (14) | 8.41 | Neutral |
| ATR (14) | 0.53 | Info |
The 30-day technical picture is mixed but leaning bullish. The RSI(14) is 60, indicating neutral-to-bullish momentum. The stock trades above the SMA50 of $19.66 and above the SMA200 of $17.89, suggesting a positive trend on a momentum basis.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.02 | $20.21 | $28.20 | 0% | Neutral | |
| $17.99 | $22.75 | $30.51 | +13% | Neutral | |
| $21.87 | $28.43 | $39.55 | +41% | Bullish | |
| $26.97 | $35.91 | $51.41 | +78% | Bullish | |
| $28.64 | $38.93 | $57.12 | +93% | Bullish | |
| $30.83 | $42.71 | $64.02 | +111% | Bullish | |
| $32.09 | $45.26 | $69.16 | +124% | Bullish | |
| $33.21 | $47.63 | $74.05 | +136% | Bullish | |
| $35.37 | $51.55 | $81.44 | +155% | Bullish | |
| $41.80 | $61.85 | $99.19 | +206% | Bullish | |
| $52.36 | $83.05 | $141.79 | +311% | Bullish | |
| $106.88 | $191.14 | $357.53 | +846% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $16.02 | $20.21 | $23.79 | +0.00% |
| June 2026 | $17.18 | $20.19 | $24.30 | -0.11% |
| July 2026 | $17.13 | $20.30 | $24.77 | +0.56% |
| August 2026 | $17.83 | $21.28 | $26.24 | +4.80% |
| September 2026 | $18.09 | $21.71 | $27.01 | +2.04% |
| October 2026 | $17.66 | $21.31 | $26.71 | -1.85% |
| November 2026 | $17.75 | $21.51 | $27.16 | +0.97% |
| December 2026 | $18.23 | $22.19 | $28.20 | +3.16% |
Click any year to see its month-by-month DNLI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect DNLI to range from $16.02 to $28.20 through 2026. The $20.21 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The DNLI price prediction for 2027 points to an average of $22.75 (low $17.99, high $30.51) — a potential gain of +13% on today's $20.21. A consolidation phase looks the most probable path here.
In 2028, DNLI is projected to trade between $21.87 and $39.55, averaging $28.43 — a potential gain of +41% from today's $20.21. That is up +25% on the projected 2027 average. Momentum favours further upside here.
Denali Therapeutics Inc.'s 2029 outlook centres on $35.91, within a $26.97 to $51.41 range. That is up +26% on the projected 2028 average. That marks a +78% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, DNLI could reach as high as $57.12, with a base case around $38.93 and support toward $28.64 — roughly +93% from $20.21. Momentum favours further upside here.
Expect DNLI to range from $30.83 to $64.02 through 2031. The $42.71 average target implies a +111% move from current prices. That is up +10% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The DNLI price prediction for 2032 points to an average of $45.26 (low $32.09, high $69.16) — a potential gain of +124% on today's $20.21. Momentum favours further upside here.
In 2033, DNLI is projected to trade between $33.21 and $74.05, averaging $47.63 — a potential gain of +136% from today's $20.21. That is up +5% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Denali Therapeutics Inc.'s 2034 outlook centres on $51.55, within a $35.37 to $81.44 range. That is up +8% on the projected 2033 average. That marks a +155% change versus current levels. Momentum favours further upside here.
By 2035, DNLI could reach as high as $99.19, with a base case around $61.85 and support toward $41.80 — roughly +206% from $20.21. Buyers look set to stay in control over this stretch.
Expect DNLI to range from $52.36 to $141.79 through 2040. The $83.05 average target implies a +311% move from current prices. That is up +34% on the projected 2035 average. Momentum favours further upside here.
The DNLI price prediction for 2050 points to an average of $191.14 (low $106.88, high $357.53) — a potential gain of +846% on today's $20.21. Buyers look set to stay in control over this stretch.
Investing $1,000 in DNLI today (≈ 49.480455 DNLI) could be worth
$9,457.94
+$8,457.94 (+846%) by 2050 · US Dollar
Based on the average projected DNLI price of $191.14 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DNLIwould be worth at today's price.
$1,000 invested in DNLI on May 27, 2025 (≈ 75.700227 DNLI) would be worth
$1,529.9
+$529.9 (+53.0%) today · 1.53× · US Dollar
Based on a DNLI entry price of $13.21 vs. today's $20.21.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $18.83 | $1,073.29 | +7.3% |
| 1 month ago | $19.94 | $1,013.54 | +1.4% |
| 3 months ago | $21.42 | $943.51 | -5.6% |
| 6 months ago | $19.47 | $1,038.01 | +3.8% |
| 1 year ago | $13.21 | $1,529.9 | +53.0% |
| All time (5.0y) ago | $61.59 | $328.14 | -67.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DNLI forecast.
Our base-case forecast reaches $40.00 around 2031.
Implied market cap at $40.00: $6.35B
The multi-year forecast depicts a rising price path with an average price of $20.21 in 2026 and $38.93 in 2030, alongside a max of $57.12 in 2030. The outlook shows sustained upside, with an average of $61.85 in 2035, $83.05 in 2040, and $191.14 in 2050. Corresponding ROI figures climb from 0% in 2026 to 12.6% in 2027, 40.7% in 2028, 77.7% in 2029, 92.7% in 2030, 111.3% in 2031, 124% in 2032, 135.7% in 2033, 155.1% in 2034, 206% in 2035, 310.9% in 2040, and 845.8% in 2050.
The sentiment shifts to bullish from 2028 onward, with high upside potential but also inherent uncertainty in forecasted outcomes. These are estimates, not guarantees, and actual results may differ.
Tap a question to reveal the answer.
The 2030 forecast shows a min of $28.64, an average of $38.93, and a max of $57.12, with an ROI of 92.7%.
Forecasts show neutral sentiment in 2026 with an average price of $20.21, then a gradual rise to $22.75 in 2027 (ROI 12.6%), $28.43 in 2028 (ROI 40.7%), $35.91 in 2029 (ROI 77.7%), and $38.93 in 2030 (ROI 92.7%), continuing higher with strong upside through 2050 (ROI 845.8%).
The 2035 max is $99.19, just under $100; the 2040 max is $141.79 and the 2050 max is $357.53.
The current price is $20.21 and the market cap is $3.21B.
The 30-day range is from $16.79 to $24.32.
Denali Therapeutics Inc. Community Discussion
0Share your Denali Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.